Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

rVSV S GP/VP40

Next Previous
Drug Profile

rVSV S GP/VP40

Alternative Names: BPSC-1001; Ebola vaccine - Merck & Co; Ebola virus vaccine - Lumos Pharma; ERVEBO; Public Health Agency of Canada's Ebola vaccine; rVSV delta G ZEBOV GP; rVSV-EBOV; rVSV-S-GP/VP40; rVSV-ZEBOV; rVSV-ZEBOV-GP; rVSVΔG-ZEBOV-GP; V-920; V920 Ebola Zaire Vaccine; VSV delta G ZEBOV; VSV delta-ZEBOV; VSV-EBOV; VSV-ZEBOV; VSVG-ZEBOV

Latest Information Update: 20 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Public Health Agency of Canada
  • Developer Canadian Immunization Research Network; Merck & Co; National Institute of Allergy and Infectious Diseases
  • Class Synthetic vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Ebola virus infections

Most Recent Events

  • 20 Jan 2026 No development reported - Phase-II for Ebola virus infections (In adolescents, Prevention, In adults) in Senegal and Burkina Faso (IM) (NCT03031912)
  • 06 Aug 2024 Merck Sharp & Dohme in collaboration with Emory University initiates a phase II trial for Ebola virus infections (Prevention) in USA (IM, Injection) (NCT06100913)
  • 20 Dec 2023 National Institute of Allergy and Infectious Diseases completes a phase II trial in Ebola virus infections (In infants, In children, In adolescents, In adults, In the elderly, Prevention) in Guinea, Liberia, Sierra Leone, Mali (IM) (NCT02876328)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top